Skip to page body Patient Care Survivorship Research Cancer Types News Giving Community Partners Clinical Trials
UCLA's Jonsson Comprehensive Cancer Center
Take the Jonsson Cancer Center Site Survey

JCCC Member Directory

Roger Lo, M.D., Ph.D.
Roger Lo, M.D., Ph.D.



General Information:



Associate Professor, Department of Medicine, Dermatology
Associate Professor, Department of Molecular and Medical Pharmacology
Member, JCCC Signal Transduction and Therapeutics Program Area

Hospital Affiliation(s):

UCLA Medical Center, Santa Monica
Ronald Reagan UCLA Medical Center


Dermatology, UCLA, 2003 - 2006
Medicine, St. Vincent's Medical Center, 2002 - 2003
Medical Degree:
M.D., Cornell University Medical College, 2002
Ph.D., Tri-Institutional Program (Cornell University Medical College, Rockefeller University, and Sloan-Kettering Institute), 2002


Board Certification(s):
Dermatology, American Board of Dermatology, 2007

Contact Information:

(310) 825-5420
(310) 917-3376 General Dermatology information and referral
(310) 267-4433 General Dermatology prescription refills
(310) 825-6911 Dermatology Surgery Clinic information and referral
(310) 267-4472 Dermatology Surgery Clinic prescription refills

Scientific Interest(s):

Dr. Roger Lo’s laboratory is focused on melanoma research in three thematic areas:
  • Discovering somatically mutated genes in melanoma using exon capture and next-generation sequencing and studying these genes in the pathogenesis of melanoma.
  • Dissecting oncogene co-dependent survival networks in melanoma using V600EB-RAF as a prototypic melanoma oncogene and siRNA library as a discovery tool.
  • Understanding the mechanisms of primary and acquired resistance to targeted therapies (including B-RAF inhibitors) using integrated genomic technologies.

Selected Cancer-Related Publications:

Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O, Reis-Filho JS, Kong X, Koya RC, Flaherty KT, Chapman PB, Kim MJ, Hayward R, Martin M, Yang H, Wang Q, Hilton H, Hang JS, Noe J, Lambros M, Geyer F, Dhomen N, Niculescu-Duvaz I, Zambon A, Niculescu-Duvaz D, Preece N, Robert L, Otte NJ, Mok S, Kee D, Ma Y, Zhang C, Habets G, Burton EA, Wong B, Nguyen H, Kockx M, Andries L, Lestini B, Nolop KB, Lee RJ, Joe AK, Troy JL, Gonzalez R, Hutson TE, Puzanov I, Chmielowski B, Springer CJ, McArthur GA, Sosman JA, Lo RS, Ribas A, Marais R. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med. 2012 Jan 19;366(3):207-15.

Shi H, Moriceau G, Kong X, Koya RC, Nazarian R, Pupo GM, Bacchiocchi A, Dahlman KB, Chmielowski B, Sosman JA, Halaban R, Kefford RF, Long GV, Ribas A, Lo RS. Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors. Cancer Discov. 2012 May;2(5):414-24. Epub 2012 Apr 1

Shi H, Moriceau G, Kong X, Lee MK, Lee H, Koya RC, Ng C, Chodon T, Scolyer RA, Dahlman KB, Sosman JA, Kefford RF, Long GV, Nelson SF, Ribas A, Lo RS. Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun. 2012 Mar 6;3:724.

Shi H, Kong X, Ribas A, Lo RS. Combinatorial treatments that overcome PDGFRBeta-driven resistance of melanoma cells to V600EB-RAF inhibition. Cancer Res. 2011 Aug 1;71(15):5067-74.

Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, Chodon T, Nelson SF, McArthur G, Sosman JA, Ribas A, Lo RS. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010 Dec 16;468(7326):973-7. Epub 2010 Nov 24